Results 211 to 220 of about 74,225 (263)

Big Data in Cancer Genomics: Computational Foundations and Emerging Pathways for Precision Oncology

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT This review aims to explore the computational foundations of big data in cancer genomics and examine emerging pathways that support precision oncology and personalized cancer care. A narrative review approach was adopted to synthesize evidence from PubMed, Scopus, Web of Science, and IEEE Xplore.
Nur Vanu, Nur Mohammad, Fahad Ahmed, Towsif Alam, Koushik Saha, Durga Shahi, Adib Hossain, Mia Md. Tofayel Gonee Manik, Mst. Rina Parvin   +8 more
wiley   +1 more source

Molecular subgroups and biomarker guided precision immunotherapy in triple-negative breast cancer: advances, challenges, and future directions. [PDF]

Front Immunol
Peng S, Qin M, Song G, Mao Q, Liu Z, Nie W.   +5 more
europepmc   +1 more source

Single‐Cell Transcriptomic Identification of Drug‐Tolerant Persister Mechanisms in Capecitabine‐Treated Triple‐Negative Breast Cancer

Computational and Systems Oncology, Volume 6, Issue 1, December 2026.
ABSTRACT Triple‐negative breast cancer (TNBC) is an aggressive subtype defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. This lack of receptors limits targeted therapies and contributes to high rates of recurrence.
Md Naiyem Islam, Md Kaziul Islam Sarkar Suja, Alif Al Takbir, Md. Kaderi Kibria   +3 more
wiley   +1 more source

Epigenetic Plasticity in Triple-Negative Breast Cancer: Mechanisms of Therapy Resistance, Biomarkers, and Therapeutic Vulnerabilities. [PDF]

Biomedicines
Alaa AR, El-Din SAB, Farrag MA, Ahmed Y, Abdel Aziz ME, Abdel-Ghany S, Arneth B, Sabit H.   +7 more
europepmc   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, Volume 159, Issue 11, Page 2633-2652, 1 December 2026.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source

Predicting Chemotherapy Response in Triple-Negative Breast Cancer: The Role of CYP2Cs as a Biomarker and a Drug Target (A Proof-of-Concept Study). [PDF]

Pharmaceuticals (Basel)
Zerouali N, Ahmed A, Jawad S, Ghanem L, Dhulkifle H, Abulola SM, Al-Maraghi G, Al-Jumaily T, Therachiyil L, Abunada HH, Al-Shar'i NA, Maayah ZH.   +11 more
europepmc   +1 more source

Synergistic Regulation of Biomaterials and Macrophages: A Novel Paradigm in Immunotherapy

MedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Bioengineered materials mediating the modulation of macrophage plasticity and inflammatory signals in the tumor microenvironment effectively remodel immunoregulatory states, boost antitumor immunity, and promote tissue repair, achieving synergistic therapeutic outcomes.
Jiayu Zhang, Songhang Xing, Shanshan Zhang, Yuan Hao, Xiaojie Qu, Wurihan Bao, Manwei Hao, Han Sun, Mingyuan Dong, Huiling Zhang, Dan Huang, Yiqi Wang, Xuanjie Jiang, Xiaoyu Pu, Yanyan Chi, Xingtong Wang, Xuefeng Li   +16 more
wiley   +1 more source

Chinese medicine-based interventions in triple-negative breast cancer: mechanistic evidence, clinical findings, and translational challenges-a narrative review. [PDF]

Front Pharmacol
Feng G, Chen C, Li T.
europepmc   +1 more source